Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

NCT00104975 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

Interventions

BIOLOGICAL: alemtuzumab
BIOLOGICAL: therapeutic allogeneic lymphocytes
DRUG: fludarabine phosphate
DRUG: melphalan
DRUG: tacrolimus
DRUG: thiotepa
PROCEDURE: peripheral blood stem cell transplantation

Sponsor

Yale University

Collaborators

[object Object]